136 related articles for article (PubMed ID: 18289047)
1. Epigenetic lesions in malignant melanoma.
Schwabe M; Lübbert M
Curr Pharm Biotechnol; 2007 Dec; 8(6):382-7. PubMed ID: 18289047
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Chen YP; Hou XY; Yang CS; Jiang XX; Yang M; Xu XF; Feng SX; Liu YQ; Jiang G
Tumour Biol; 2016 Aug; 37(8):11209-18. PubMed ID: 26943799
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
4. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Schraml P; von Teichman A; Mihic-Probst D; Simcock M; Ochsenbein A; Dummer R; Michielin O; Seifert B; Schläppi M; Moch H; von Moos R
Oncol Rep; 2012 Aug; 28(2):654-8. PubMed ID: 22614944
[TBL] [Abstract][Full Text] [Related]
8. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
9. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
Murgo AJ
Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
[TBL] [Abstract][Full Text] [Related]
10. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells.
Mori T; Kim J; Yamano T; Takeuchi H; Huang S; Umetani N; Koyanagi K; Hoon DS
Cancer Res; 2005 Mar; 65(5):1800-7. PubMed ID: 15753377
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma.
Venza M; Visalli M; Biondo C; Lentini M; Catalano T; Teti D; Venza I
Biochim Biophys Acta; 2015 Mar; 1849(3):247-56. PubMed ID: 25497382
[TBL] [Abstract][Full Text] [Related]
14. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
Claus R; Almstedt M; Lübbert M
Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
[TBL] [Abstract][Full Text] [Related]
17. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Therapeutics: A New Weapon in the War Against Cancer.
Ahuja N; Sharma AR; Baylin SB
Annu Rev Med; 2016; 67():73-89. PubMed ID: 26768237
[TBL] [Abstract][Full Text] [Related]
19. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
